Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/205204
Title: Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop
Author: Quintanilla Martinez, Leticia
Laurent, Camille
Soma, Lorinda
Ng, Siok Bian
Climent, Fina
Ondrejka, Sarah L.
Zamo, Alberto
Wotherspoon, Andrew
Leval, Laurence de
Dirnhofer, Stefan
Leoncini, Lorenzo
Keywords: Limfomes
Translocació (Genètica)
Lymphomas
Translocation (Genetics)
Issue Date: 9-Aug-2023
Publisher: Springer Science and Business Media LLC
Abstract: Emerging entities and molecular subgroups in large B-cell lymphomas (LBCLs) were discussed during the 2022 European Association for Haematopathology/Society for Hematopathology workshop in Florence, Italy. This session focused on newly recognized diseases and their diagnostic challenges. High-grade/large B-cell lymphoma with 11q aberration (HG/LBCL-11q) is defined by chromosome 11q-gains and telomeric loss. FISH analysis is recommended for the diagnosis. HG/LBCL-11q can occur in the setting of immunodeficiency, including ataxia-telangiectasia, and predominates in children. The morphological spectrum of these cases is broader than previously thought with often Burkitt-like morphology and coarse apoptotic bodies. It has a Burkitt-like immunophenotype (CD10+, BCL6+, BCL2-) but MYC expression is weak or negative, lacks MYC rearrangement, and is in contrast to Burkitt lymphoma 50% of the cases express LMO2. LBCL with IRF4 rearrangement (LBCL-IRF4) occurs mainly in the pediatric population but also in adults. LBCL-IRF4 has an excellent prognosis, with distinguishing molecular findings. IRF4 rearrangements, although characteristic of this entity, are not specific and can be found in association with other chromosomal translocations in other large B-cell lymphomas. Other molecular subgroups discussed included primary bone diffuse large B-cell lymphoma (PB-DLBCL), which has distinctive clinical presentation and molecular findings, and B-acute lymphoblastic leukemia (B-ALL) with IGH::MYC translocation recently segregated from Burkitt lymphoma with TdT expression. This latter disorder has molecular features of precursor B-cells, often tetrasomy 1q and recurrent NRAS and KRAS mutations. In this report, novel findings, recommendations for diagnosis, open questions, and diagnostic challenges raised by the cases submitted to the workshop will be discussed.
Note: Reproducció del document publicat a: https://doi.org/10.1007/s00428-023-03590-x
It is part of: Virchows Archiv, 2023, vol. 483, num. 3, p. 281-298
URI: http://hdl.handle.net/2445/205204
Related resource: https://doi.org/10.1007/s00428-023-03590-x
ISSN: 1432-2307
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
s00428-023-03590-x.pdf4.05 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons